Sign In
Buy YMAB
$8.61
+0 (+0%)
At Close: Dec 15, 2025
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2023 Earnings Call Transcript
03:22pm, Tuesday, 14'th Nov 2023
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q3 2023 Results Conference Call November 14, 2023 9:00 AM ET Company Participants Courtney Dugan - Vice President of Investor Relations Michael Rossi - Preside
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
06:47pm, Monday, 13'th Nov 2023
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.63 per share a year ago.
All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy
01:31pm, Wednesday, 08'th Nov 2023
Y-mAbs Therapeutics, Inc. (YMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
07:05am, Tuesday, 31'st Oct 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter
Y-mAbs: They Have Earnings, But Still Seek The Big Hit
07:14pm, Wednesday, 11'th Oct 2023
Y-mAbs Therapeutics is undervalued despite growing sales of their approved cancer therapy, presenting an opportunity for investors. Their approved product, naxitamab, has shown positive response rates
Y-mAbs to Participate at Upcoming Investor Conferences in September
04:05pm, Wednesday, 06'th Sep 2023
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and c
Y-mAbs Therapeutics, Inc. (YMAB) Q2 2023 Earnings Call Transcript
04:43pm, Friday, 11'th Aug 2023
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2023 Earnings Call Transcript August 11, 2023 9:00 AM ET Company Participants Courtney Dugan - Head of IR Thomas Gad - Founder, President & Interim CEO Vign
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
06:16pm, Thursday, 10'th Aug 2023
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.94 per share a year ago.
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
04:05pm, Tuesday, 01'st Aug 2023
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarte
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2023 Earnings Call Transcript
05:16am, Sunday, 14'th May 2023
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, President, Interim Chief Executive Officer Sue Smith - Senio
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
07:03pm, Monday, 08'th May 2023
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.64 per share a year ago.
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
09:00am, Friday, 28'th Apr 2023
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ende
Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade
11:26am, Wednesday, 05'th Apr 2023
The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend i
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?
06:52am, Tuesday, 04'th Apr 2023
Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
07:12pm, Thursday, 30'th Mar 2023
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
